Gan & Lee Pharmaceuticals’ GZR4 Ultra-Long-Acting Insulin Receives Clinical Trial Approval
China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that its Category 1 therapeutic biologic product...
Gan & Lee Pharmaceuticals
Gan & Lee Pharmaceuticals Doses First Patient in GZR101 Phase I Study
China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that the first patient has been dosed...